126 related articles for article (PubMed ID: 8365641)
21. Effect of ebrotidine on gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide.
Slomiany BL; Piotrowski J; Slomiany A
J Physiol Pharmacol; 1999 Sep; 50(3):391-404. PubMed ID: 10574469
[TBL] [Abstract][Full Text] [Related]
22. Cell cycle progression during gastric ulcer healing by ebrotidine and sucralfate.
Slomiany BL; Piotrowski J; Slomiany A
Gen Pharmacol; 1997 Sep; 29(3):367-70. PubMed ID: 9378241
[TBL] [Abstract][Full Text] [Related]
23. Glycosulfatase activity of Helicobacter pylori towards gastric sulfomucin: effect of nitecapone.
Slomiany BL; Murty VL; Piotrowski J; Morita M; Slomiany A
J Physiol Pharmacol; 1993 Mar; 44(1):7-16. PubMed ID: 8518427
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of Helicobacter pylori urease activity by ebrotidine.
Piotrowski J; Slomiany A; Slomiany BL
Biochem Mol Biol Int; 1995 Oct; 37(2):247-53. PubMed ID: 8673007
[TBL] [Abstract][Full Text] [Related]
25. Effects of ebrotidine on aspirin-induced gastric mucosal damage and blood flow in humans.
Konturek SJ; Kwiecien N; Sito E; Obtulowicz W; Kaminski K; Oleksy J
Scand J Gastroenterol; 1993 Dec; 28(12):1047-50. PubMed ID: 7905660
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of EGF-induced gastric mucosal calcium channel phosphorylation by ebrotidine.
Slomiany BL; Liu J; Piotrowski J; Slomiany A
Biochem Int; 1992 Dec; 28(4):751-60. PubMed ID: 1282815
[TBL] [Abstract][Full Text] [Related]
27. Effect of ebrotidine on ethanol-induced gastric mucosal damage in the rat. Comparative study with other H2-receptor antagonists.
Palop D; Romero A; Villamayor F; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):450-4. PubMed ID: 9205742
[TBL] [Abstract][Full Text] [Related]
28. Enhancement in the protective qualities of gastric mucus with combination therapy of ebrotidine and amoxicillin for H. pylori eradication.
Slomiany BL; Piotrowski J; Slomiany A; Konturek JW; Domschke WW
Gen Pharmacol; 1998 Aug; 31(2):227-31. PubMed ID: 9688464
[TBL] [Abstract][Full Text] [Related]
29. Gastric mucosal laminin receptor expression with ulcer healing by ebrotidine.
Slomiany BL; Piotrowski J; Czajkowski A; Yotsumoto F; Majka J; Slomiany A
Gen Pharmacol; 1994 May; 25(3):451-5. PubMed ID: 7926589
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Helicobacter pylori glycosulfatase activity towards human gastric sulfomucin by a gastroprotective agent, sulglycotide.
Murty VL; Piotrowski J; Czajkowski A; Slomiany A; Slomiany BL
Gen Pharmacol; 1993 Nov; 24(6):1463-6. PubMed ID: 8112521
[TBL] [Abstract][Full Text] [Related]
31. Ebrotidine.
Patel SS; Wilde MI
Drugs; 1996 Jun; 51(6):974-80; discussion 981. PubMed ID: 8736619
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of gastric mucosal laminin receptor by Helicobacter pylori lipopolysaccharide: effect of ebrotidine.
Piotrowski J; Morita M; Slomiany A; Slomiany BL
Biochem Int; 1992 Jun; 27(1):131-8. PubMed ID: 1385705
[TBL] [Abstract][Full Text] [Related]
33. Gastric mucosal apoptosis induced by ethanol: effect of antiulcer agents.
Piotrowski J; Piotrowski E; Skrodzka D; Slomiany A; Slomiany BL
Biochem Mol Biol Int; 1997 Jun; 42(2):247-54. PubMed ID: 9238522
[TBL] [Abstract][Full Text] [Related]
34. Effect of Helicobacter pylori lipopolysaccharide on the synthesis of sulfated gastric mucin.
Slomiany BL; Liau YH; Lopez RA; Piotrowski J; Czajkowski A; Slomiany A
Biochem Int; 1992 Aug; 27(4):687-97. PubMed ID: 1417902
[TBL] [Abstract][Full Text] [Related]
35. Studies on the cytoprotective and antisecretory activity of ebrotidine. A review.
Konturek PC; Brzozowski T; Konturek SI; Márquez M; Torres J; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):578-89. PubMed ID: 9205769
[TBL] [Abstract][Full Text] [Related]
36. Role of sulphation in post-translational processing of rat salivary mucins.
Slomiany BL; Liau YH; Li Q; Fekete Z; Slomiany A
Arch Oral Biol; 1991; 36(11):785-90. PubMed ID: 1763975
[TBL] [Abstract][Full Text] [Related]
37. Study on the increment of the amount of gastric mucus in rats after repeated-dose administration of ebrotidine.
Romero A; Villamayor F; Palop D; Falcó J; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):455-8. PubMed ID: 9205743
[TBL] [Abstract][Full Text] [Related]
38. Effect of ebrotidine on gastric mucosal EGF and PDGF receptor expression.
Piotrowski J; Czajkowski A; Yotsumoto F; Slomiany A; Slomiany BL
Biochem Mol Biol Int; 1993 Aug; 30(6):1127-34. PubMed ID: 8106073
[TBL] [Abstract][Full Text] [Related]
39. Gastroprotective and ulcer-healing activities of a new H2-receptor antagonist: ebrotidine.
Brzozowski T; Majka J; Konturek SJ
Digestion; 1992; 51(1):27-36. PubMed ID: 1353465
[TBL] [Abstract][Full Text] [Related]
40. Gastric acid inhibitory profile of ebrotidine, a novel H2-receptor antagonist in humans.
Maczka M; Kwiecień N; Obtułowicz W; Konturek SJ; Kamiński K; Oleksy J; Gabryelewicz A; Torres J
J Physiol Pharmacol; 1992 Jun; 43(2):139-48. PubMed ID: 1356519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
